Primary CNS Lymphoma Basics To Brilliance: Haematology podcast

Basics to Brilliance: Haematology Podcast « »

3M ago 1:09:06

Μοίρασέ το

Το περιεχόμενο παρέχεται από το Basics To Brilliance. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον Basics To Brilliance ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

CNS Lymphomas

1% of all NHL
3% of all Brain tumours
Most common subtype (90%) is DLBCL

Clinical division:
1. 1* CNS lymphoma,
2. 2* CNS lymphoma
- TN-SCNSL
- RI-SCNSL
- RC-SCNSL
3. Immune deficiency assoc- HIV; better prog.

Presentation:
- SOL Sx
- Raised ICP: morning headaches w N+V
- Neuropsych, Behavioural, Memory, Language
- Focal motor + Stroke Sx
- Seizures
- Visual Sx and uveitis

Investigations:
- FBC + Blood film (exclude 2* CNS lymphoma and BM), GFR, U&Es
- LDH (prog.)
- Virology (Hep+HIV)
- IGs, SPEp (paraprotein)
- Stereotactic Brain Bx w/ IO rapid cytology and rv of frozen sections
NB: Steroids pre-biopsy ?non-diagnostic results
- LP:
.Leptomeningeal*
.CSF protein- prognostic
.Flow
.Cytospin
.PCR for IGHV r.
- CT Head
- MRI H (w gadolinium) +/- spine

Staging:
-R/O systemic lymphoma
-PET/CT
-US Testes
-Opthalmoscopy/fundoscopy +/- Vitreal biopsy +/- subretinal aspirate
-?BMBx

Pre-treatment:
-Baseline neuropsych + cognitive ax
-Premorbid performance status: ECOG, Echo, GFR, PMHx

Dx w/o Bx
-MRI
-Clinical features
-Clonal B cells in CSF/Vitreous fluid and/or PCR IGHV rearrangement
Treatment:
Induction main:
- MATRIX- younger <70
- MARTA- older >65
Consolidation:
- Whole brain RT
- BCNU Thiotepa AutoSCT- gold standard if fit...Within 6-8 weeks of the 1st day of final induction: consider for all patients with non-progressive disease (EOT MRI)

Trials:
IELSG32 study (Leukemia, 2022)- induction + consolidation choices for < 70
Induction: 3 arms, MTX + Cyt main
- MATRIX- MTX +Cyt + Thiotepa + Ritux -> AutoSCT…..best choice (4 cycles)...7yr 70% survival
Consolidation: efficacy equal AutoSCT and WB-RT, favoured AutoSCT for Sx.
...MATRIX regimen available on NSSG:
- Dose ++ to cross BBB
- Folinic Acid rescue*
- IVF till MTX levels <0.1 umol/L (1st lvl 48hrs after MTX)
- EF >45%
- GFR >50
NB: stop co-trimoxazole, penicillins, aspirin, NSAIDs, PPIs (inhibit MTX clearance)
- MTX build up in 3rd spaces
- Stem cell harvest post #2
- Treatment related mortality 4-7% mostly in #1
- Dose reduce Cytaribin (2/3instead of 4 cycles) if pre-morbid, 25-50% total

MARTA study (Blood, Nov 22): fit for autosct and >65
- 2x MTX, cytarabin and rituximab ->AutoSCT

PRIMAIN study(2017): not fit for autosct >= 65
1. 4x MTX, Ritux + PO procarbazine
2. 6mo of PO procarbazine as maintenance
?WB-RT for residual disease

- Palliative if unfit and older:
Dex
Temozolomide
WB-RT
?IT Chemo in leptomeningeal

IELSG43 study… favoured AutoSCT PFS and OS to de-escalation consol.

Follow Up:
- Response Ax with contrast enhanced MRI scan: 1-2mo after consol.
- Rpt MRI every 3-4mo for 2 years ++-
- CR: MRI NAD, normal eye, clear CSF
- Stable: <50% decrease, <25% increase
- PR: 50% tumor reduction ?persistent CSF
- Progressive: >25% increase and/or new lesions
- Relapse/Refractory
25% asymptomatic
OS 3-5mo
?Trial
Re-Bx and r/o other brain tumors
Restaging
Re-induction w/ salvage chemo
.MATRix if remission > 2 years +/- WB-RT if post auto
.Ifosfamide based: RICE or RIE

Future:
2nd gen BTKis- Ibrutinib or Zanibrutinib

5 επεισόδια